Article

Role of the SurvivinGene in Pathophysiology

Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.
American Journal Of Pathology (Impact Factor: 4.6). 08/2006; 169(1):1-11. DOI: 10.2353/ajpath.2006.060121
Source: PubMed

ABSTRACT Although the roles of survivin in control of cancer cell division and apoptosis as well as targeting survivin for cancer therapeutics have been extensively explored and reviewed, the pathophysiological role of survivin in normal human cells/organs has not been deeply investigated or sufficiently reviewed. Studies in the latter area, however, appear to be important for the identification of different mechanisms of regulation and function of survivin in normal versus abnormal cells and tissues (including cancer), which might ultimately provide the basis for novel approaches for disease treatment with low toxicity. This Review is intended to summarize current observations in the literature related to the physiological and/or pathological roles for survivin in various normal human cells or organs. Our view of potential future research directions for survivin pertinent to potential therapeutic applications will also be discussed.

Download full-text

Full-text

Available from: Fengzhi Li, Jun 19, 2014
0 Followers
 · 
105 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: In order to eliminate common side effects to cancer patients and resistance from chemotherapy, a genetic protein TmSm(T34A) was investigated as a sensitizer to doxorubicin. The results indicated TmSm(T34A) enhanced the sensitivity of three breast cancer cell lines to doxorubicin with low dose, and reduced the dose of doxorubicin significantly in contrast to common effective dose. As a synergistic therapy, the TmSm(T34A) also caused strongest apoptotic activity in MCF-7, and the possible molecular mechanisms were explored primarily. The research showed the TmSm(T34A) is promising to be a potential drug in strengthening therapy effects of breast cancer chemotherapy.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 02/2012; 66(5):368-72. DOI:10.1016/j.biopha.2011.12.004 · 2.11 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Survivin protein accomplishes two basic functions: cell cycle regulation and control of apoptosis. It is only expressed in G2/M phase and it influences rescue pathways in apoptosis-induced cells. Overexpression of constitutive active c-H-ras in HeLa, or induction of c-H-ras in a stable HeLaDiR cell line, led to sustained survivin expression in all cell cycle phases and even protected cells from drug induced apoptosis. siRNA-mediated silencing of survivin reversed this protection. Here we link the anti-apoptotic property of survivin to its cell cycle (in)dependent regulation via the activity of oncogenic c-H-ras.
    FEBS Letters 11/2007; 581(25):4921-6. DOI:10.1016/j.febslet.2007.09.023 · 3.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Survivin ist das kleinste Mitglied der Inhibitor-of-apoptosis-protein(IAP)-Gen-Familie und erfüllt entscheidende Aufgaben in der Regulation des Zellzyklusses und des zellulären Überlebens. Diese Funktionen wurden bisher lediglich in Tumoren, der Embryonalentwicklung und in einzelnen hochdifferenzierten Geweben beobachtet. Im Rahmen dieser Studie wird über die Expression des onkofetalen Gens Survivin in primären humanen chondrozytären Kulturen und dessen Reexpression im osteoarthrotisch veränderten Gelenkknorpel berichtet. Des Weiteren konnte ein ausgeprägter Einfluss des Gens auf Zellzyklus und Zellüberlebensentscheidungen in primären humanen Chondrozyten nachgewiesen werden. Diese Funktionen sind für die Aufrechterhaltung der kartilaginären Integrität essenziell und limitieren die In-vitro-Kultivierung von autologem Knorpelersatz. Die Modulation der Survivinexpression und Funktion in Chondrozyten könnte zukünftig eine Rolle im Rahmen regenerativer Knorpeltherapieverfahren einnehmen.
    Der Orthopäde 04/2012; 41(4). DOI:10.1007/s00132-011-1852-0 · 0.67 Impact Factor